BM8 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Biomarin Pharmaceutical Inc

Watchlist Manager

Watchlist

Price: 57.48 EUR Market Closed

Market Cap: €10.9B

B	Biomarin Pharmaceutical Inc XMUN:BM8	US
S	Semperit Holding AG VSE:SEM	AT
L	Lepidico Ltd F:AUB	AU
	Adicet Bio Inc NASDAQ:ACET	US
N	Netflix Inc SWB:NFC	US
	Sensorion SA PAR:ALSEN	FR
Q	Quality Industrial Corp OTC:QIND	US

Profitability Summary

Biomarin Pharmaceutical Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

80%

Strong 3Y Average Gross Margin

80%

Gross Margin is Increasing

78% > 80%

Healthy Operating Margin

20%

Sustainable 3Y Average Operating Margin

18%

Operating Margin is Increasing

4% > 20%

Low Net Margin

Sustainable 3Y Average Net Margin

11%

Declining Net Margin

4% > 2%

Exceptional Free Cash Flow Margin

21%

Strong 3Y Average Free Cash Flow Margin

15%

Free Cash Flow Margin is Increasing

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.